WallStSmart

Moderna Inc (MRNA)vsMaravai Lifesciences Holdings Inc (MRVI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 967% more annual revenue ($2.23B vs $208.78M). MRVI leads profitability with a -37.1% profit margin vs -141.4%. MRVI earns a higher WallStSmart Score of 22/100 (F).

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09

MRVI

Avoid

22

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 2/9Altman Z: 0.32
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Intrinsic value data unavailable for MRVI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

MRVI0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

MRVI4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-49.4%2/10

ROE of -49.4% — below average capital efficiency

EPS GrowthGrowth
-32.7%2/10

Earnings declined 32.7%

Altman Z-ScoreHealth
0.322/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bull Case : MRVI

MRVI has a balanced fundamental profile.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Bear Case : MRVI

The primary concerns for MRVI are Piotroski F-Score, Return on Equity, EPS Growth.

Key Dynamics to Monitor

MRNA carries more volatility with a beta of 1.11 — expect wider price swings.

MRVI is growing revenue faster at 8.5% — sustainability is the question.

MRVI generates stronger free cash flow (4M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRVI scores higher overall (22/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Maravai Lifesciences Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?